We analyzed trending and awareness patterns of NTRK and NTRK-targeting compounds in academic and community oncologists.

Awareness of new and emerging cancer biomarkers and compounds is vital so HCPs will test for and treat molecular oncogenic drivers.

Patient advocacy groups provide support, education, advocacy, and information sharing while including the patient perspective in healthcare.